The first product from AbbVie's $8.7 billion takeover of Cerevel two years ago – Parkinson's disease therapy tavapadon – has ...

Der EMA-Ausschuss für Humanarzneimittel (CHMP) sprach sich für die Zulassung von Hopledo aus. Das Präparat kombiniert Levodopa und Carbidopa in retardierter Form. Parallel dazu erhielt Produodopa ...

アッヴィは、2022年の第3四半期に、分散審査方式を通じて、PRODUODOPAの製造販売承認を取得しました。 PRODUODOPA皮下投与用VYAFUSER™ポンプは、2023年11月に欧州適合（CE）マークを取得しました。

PRODUODOPAは、他の治療法では症状の制御が不十分な進行期パーキンソン病患者さんにおける重度の運動機能の日内変動を治療するための、初めてかつ唯一の、レボドパベースの24時間持続投与可能な皮下注射剤です。PRODUODOPAの継続的投与により、レボドパを1日24時間投与することができます ...

AbbVie announced the launch of Produodopa (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson's disease with severe motor ...

Gütersloh. Wolfgang Kurrek leidet seit 15 Jahren an der Parkinson-Krankheit. „Es fing damals mit Zittern im linken Arm an“, erzählt der 69-Jährige. Im Verlauf der Jahre verschlechterten sich die ...

编辑推荐：针对口服左旋多巴/卡比多帕难以控制的晚期帕金森病(PD)运动波动，研究人员通过随机双盲双模拟试验证实，24小时 ...

A County Durham man with Parkinson's disease has become one of the first patients in the country to receive a pioneering drug that "dramatically improves" the condition. Anthony Quinn, 49 and from ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to innovative cell and gene therapies. Over the past decade, researchers have ...

Pasient - og brukerombud Jannicke Bruvik kritiserer forskjellsbehandling av parkinson-pasienter i Norge. En ny og mer effektiv metode for å tilføre kroppen Parkinson-medisin, Produodopa, tilbys bare ...

Parkinsons sykdom er den raskest voksende hjernesykdommen i den vestlige verden, og det anslås at opptil 13.000 personer har sykdommen i Norge. Produodopa ble godkjent på markedet i Norge for 18 ...